In a press release earlier, Sarepta Therapeutics announced results of an interim analysis of the casimersen part of their late stage, phase 3 ESSENCE …
Sarepta Therapeutics announces preliminary results in casimersen (exon 45 skipping) trialRead More
A recently published study has found that boys treated with daily Deflazacort (a corticosteroid) have more fractures than boys treated with other …
We are delighted to announce that television and radio broadcaster Jonny Gould has become an ambassador for Action Duchenne. Jonny is a presenter and …
Jonny Gould becomes an Ambassador for Action DuchenneRead More
We are delighted to announce our friends and long-time supporters of the charity, Trevor and Lucy, are our new Action Duchenne Ambassadors! Lucy …
Trevor and Lucy become Ambassadors for Action DuchenneRead More
Raxone (also known as Idebenone) is a drug produced by Santhera Pharmaceuticals, which treats several conditions and has the potential to treat …
In a press release, Santhera Pharmaceuticals has announced results from the SYROS study, where long-term treatment with idebenone (also known as …
This weekend our Director of Research, Neil Bennett, and our CEO, Shelley Simmonds, are in Rome attending the Duchenne Parent Project International …
Last weekend, our wonderful supporters Stoke By Nayland Golf Club held their much anticipated raffle draw. The prize was a week in a luxury villa …
Solid Biosciences have announced preliminary data from their phase 1/2 IGNITE-DMD clinical trial that is testing the safety and effectiveness of …
Solid Biosciences announce preliminary trial resultsRead More
PTC Therapeutics had their annual kick-off meeting in Cascais, outside of Lisbon from 28th January to the 1st of February. Cormac Fegan, age 8, and …
An update from our Scottish Advocacy Officer, John Miller: "At a Disability Cross Party meeting on the 27th November 2018, the Secretary of …
